Wall Street Journal editors support aducanumab approvalhttps://www.wsj.com/articles/the-battle-over-an-alzheimers-treatment-11618873596
Last line in the article:
The U.S. may be on the cusp of an Alzheimer’s breakthrough, and the FDA’s first duty is to patients.